Literature DB >> 19786020

Huntington's disease: silencing a brutal killer.

Edith L Pfister1, Phillip D Zamore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19786020      PMCID： PMC2805437          DOI： 10.1016/j.expneurol.2009.09.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  40 in total

1.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

2.  Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference.

Authors:  Natasha J Caplen; J Paul Taylor; Victoria S Statham; Fumiaki Tanaka; Andrew Fire; Richard A Morgan
Journal:  Hum Mol Genet       Date:  2002-01-15       Impact factor: 6.150

3.  Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.

Authors:  Yu-Lai Wang; Wanzhao Liu; Etsuko Wada; Miho Murata; Keiji Wada; Ichiro Kanazawa
Journal:  Neurosci Res       Date:  2005-08-10       Impact factor: 3.304

4.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

Authors:  R R Brinkman; M M Mezei; J Theilmann; E Almqvist; M R Hayden
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

5.  Trinucleotide repeat length instability and age of onset in Huntington's disease.

Authors:  M Duyao; C Ambrose; R Myers; A Novelletto; F Persichetti; M Frontali; S Folstein; C Ross; M Franz; M Abbott
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.

Authors:  Yoko Machida; Takashi Okada; Masaru Kurosawa; Fumitaka Oyama; Keiya Ozawa; Nobuyuki Nukina
Journal:  Biochem Biophys Res Commun       Date:  2006-03-03       Impact factor: 3.575

7.  Allele-specific silencing of mutant Huntington's disease gene.

Authors:  Yu Zhang; Joshua Engelman; Robert M Friedlander
Journal:  J Neurochem       Date:  2009-01       Impact factor: 5.372

8.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Authors:  Mark E Kleinman; Kiyoshi Yamada; Atsunobu Takeda; Vasu Chandrasekaran; Miho Nozaki; Judit Z Baffi; Romulo J C Albuquerque; Satoshi Yamasaki; Masahiro Itaya; Yuzhen Pan; Binoy Appukuttan; Daniel Gibbs; Zhenglin Yang; Katalin Karikó; Balamurali K Ambati; Traci A Wilgus; Luisa A DiPietro; Eiji Sakurai; Kang Zhang; Justine R Smith; Ethan W Taylor; Jayakrishna Ambati
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

9.  Sustained effects of nonallele-specific Huntingtin silencing.

Authors:  Valérie Drouet; Valérie Perrin; Raymonde Hassig; Noëlle Dufour; Gwennaelle Auregan; Sandro Alves; Gilles Bonvento; Emmanuel Brouillet; Ruth Luthi-Carter; Philippe Hantraye; Nicole Déglon
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

10.  Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

Authors:  Edith L Pfister; Lori Kennington; Juerg Straubhaar; Sujata Wagh; Wanzhou Liu; Marian DiFiglia; Bernhard Landwehrmeyer; Jean-Paul Vonsattel; Phillip D Zamore; Neil Aronin
Journal:  Curr Biol       Date:  2009-04-09       Impact factor: 10.834
View more
  9 in total

Review 1.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

2.  Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

Authors:  Jiaxin Hu; Jing Liu; David R Corey
Journal:  Chem Biol       Date:  2010-11-24

3.  A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression.

Authors:  Daniel W Chung; Dobrila D Rudnicki; Lan Yu; Russell L Margolis
Journal:  Hum Mol Genet       Date:  2011-06-13       Impact factor: 6.150

4.  Targeting individual calpain isoforms for neuroprotection.

Authors:  James W Geddes; Kathryn E Saatman
Journal:  Exp Neurol       Date:  2010-08-03       Impact factor: 5.330

5.  Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

Authors:  Jeffrey B Carroll; Simon C Warby; Amber L Southwell; Crystal N Doty; Sarah Greenlee; Niels Skotte; Gene Hung; C Frank Bennett; Susan M Freier; Michael R Hayden
Journal:  Mol Ther       Date:  2011-10-04       Impact factor: 11.454

6.  Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Authors:  Ken Yamada; Samuel Hildebrand; Sarah M Davis; Rachael Miller; Faith Conroy; Ellen Sapp; Jillian Caiazzi; Julia F Alterman; Loic Roux; Dimas Echeverria; Matthew R Hassler; Edith L Pfister; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

Review 7.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

Review 8.  State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014-09       Impact factor: 2.970

Review 9.  Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.

Authors:  Marta Carvalho; Bruno Sepodes; Ana Paula Martins
Journal:  Front Med (Lausanne)       Date:  2017-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.